Organization (Academic)
Gachon University
ClinicalTrials.gov lists Gachon University as lead sponsor of 92 trials, counting the companies grouped under it. Gachon University itself has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
16 sections measured, none recorded
This page covers Gachon University and 1 company grouped under it: 92 lead-sponsored trials (2 its own, 90 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Gachon University Gil Medical Center | 90 | 1 |
Disease areas (116)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Insulin Resistance | 14 |
| Dyslipidemias | 12 |
| Hyperlipidemias | 12 |
| Colorectal Neoplasms | 10 |
| Coronary Artery Disease | 8 |
Showing 5 of 116 disease areas.
Trials by start year as sponsor or collaborator (2)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2017 | 1 |
No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Treatment As Usual | Major Depressive Disorder | Not reported | 1 |
Journals published in (129)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 8 |
| Gastrointestinal endoscopy | 6 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 5 |
| Journal of the American College of Cardiology | 5 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 4 |
Showing 5 of 129 journals.
Organization relationships (65)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Seoul National University | Co sponsors trial with | 25 |
| Yonsei University | Co sponsors trial with | 15 |
| Chungnam National University | Co sponsors trial with | 7 |
| Samsung (South Korea) | Co sponsors trial with | 7 |
| Asan Foundation | Co sponsors trial with | 7 |
Showing 5 of 65 relationships.
Latest dated events (130)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 130 events.
Biomarkers this organization publishes on (382)
Shown in this order: most publications first.
Showing 5 of 382 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, approved assets, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarker capability evidence.